JPMorgan raised the firm’s price target on Danaher to $300 from $270 and keeps an Overweight rating on the shares. The analyst views the company’s 2024 guidance as achievable and is encouraged by the potential upside in the event of a bioprocessing order inflection. The firm continues to believe Danaher is a name to own in 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DHR:
- Danaher Corporation Reports Earnings: Did it Beat Estimate Forecasts?
- Danaher (NYSE:DHR) Drops on Dismal Q4 Numbers
- Danaher sees FY24 revenue down low-single digits, consensus $24.05B
- Danaher sees Q1 revenue down high-single digits, consensus $5.73B
- Danaher Reports Fourth Quarter and Full Year 2023 Results
